Merritt J C, Perry D D, Russell D N, Jones B F
J Clin Pharmacol. 1981 Aug-Sep;21(S1):467S-471S. doi: 10.1002/j.1552-4604.1981.tb02626.x.
Systemic delta 9-tetrahydrocannabinol (THC), administered either by smoking marihuana or as synthetic THC in soft gelatin capsules, lowers ocular tension in various glaucomas, but at the expense of significant decreases in systolic blood pressure. Topical THC in light mineral oil vehicles, though effective in laboratory animals, was not shown effective in 0.05 and 0.1% topical solutions when administered to six subjects with primary open-angle glaucoma in a randomized, balanced, double-masked protocol. Light mineral oil, which has an affinity for corneal epithelium, is an optimum vehicle for administering drugs whose mechanisms of action are systemic rather than local within the eye. Further glaucoma research should therefore proceed with marihuanas containing insignificant levels of THC (less than 0.4%) and with various local delivery systems of the ocular-active cannabinoid found in Cannabis sativa.
通过吸食大麻或服用软胶囊形式的合成Δ9-四氢大麻酚（THC）来进行全身性给药，可降低各种青光眼患者的眼压，但代价是收缩压显著下降。在轻质矿物油载体中的局部THC，尽管在实验动物中有效，但在一项随机、平衡、双盲试验中，当以0.05%和0.1%的局部溶液形式给予6名原发性开角型青光眼患者时，未显示出有效性。轻质矿物油对角膜上皮有亲和力，是一种用于给药作用机制为全身性而非眼部局部性药物的理想载体。因此，进一步的青光眼研究应采用THC含量极低（低于0.4%）的大麻以及大麻中发现的眼部活性大麻素的各种局部给药系统来进行。
